M
Madrigal Pharmaceuticals, Inc. (MDGL)
NMS – Real Time Price. Currency in USD
510.26
+13.23 (2.66%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
510.26
+13.23 (2.66%)
At close: May 12, 2026, 4:00 PM EDT
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
| Name | Position |
|---|---|
| Dr. David Soergel M.D. | Executive VP & Chief Medical Officer |
| Dr. Rebecca A. Taub M.D. | Founder, Senior Scientific & Medical Advisor and Director |
| Mr. Mark Underwood | Executive Vice President of Business Planning & Operations |
| Mr. Ronald Filippo | Executive VP & Chief Information Officer |
| Mr. William J. Sibold | CEO, President & Director |
| Ms. Carole Huntsman | Executive VP & Chief Commercial Officer |
| Ms. Mardi C. Dier | Executive VP & CFO |
| Ms. Rita Thakkar | Senior VP & Chief Accounting Officer |
| Ms. Shannon Kelley | Executive VP, Chief Legal Officer & Corporate Secretary |
| Ms. Tina E. Ventura | Chief Investor Relations Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 8-K | mdgl-20260506.htm |
| 2026-05-06 | 10-Q | mdgl-20260331.htm |
| 2026-04-28 | DEFA14A | tm261619d3_defa14a.htm |
| 2026-02-19 | 10-K | mdgl-20251231.htm |
| 2026-01-30 | 8-K | tm264540d1_8k.htm |
| 2025-12-11 | 8-K | mdgl-20251205.htm |
| 2025-11-04 | 8-K | mdgl-20251104.htm |
| 2025-09-11 | S-8 | tm2525766d1_s8.htm |
| 2025-08-05 | 8-K | mdgl-20250805.htm |
| 2025-08-05 | 10-Q | mdgl-20250630.htm |